Long-Term Side Effects of Wegovy: What the Evidence Actually Shows

What the decision actually hinges on

When people ask about long-term side effects of Wegovy, they're usually not asking out of abstract curiosity. They're trying to decide whether starting, continuing, or stopping treatment is the right call. That's a clinical decision, and it rests on three things: what the evidence shows so far, where genuine uncertainty remains, and what your own health history adds to the picture. Semaglutide 2.4mg (the active ingredient in Wegovy) has now been studied across thousands of adults in large controlled trials, and it has a post-market surveillance record that few newer medicines can match. But licensed weight-management treatment with Wegovy extends up to two years under NICE guidance, and data beyond that window is still being gathered. Sitting with that honestly is part of responsible prescribing. You can read a fuller breakdown of Wegovy's side-effect profile if you want the wider picture before weighing up what follows here.

What happens to most people over months, not just weeks

The pattern of side effects over longer use matters more than what happens in the first fortnight. In the STEP 1 trial, published in the New England Journal of Medicine, the most common adverse events across 68 weeks were gastrointestinal: nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These were generally mild to moderate in severity. Critically, their frequency declined after the maintenance dose was reached. Injection-site reactions, headache, and fatigue were also reported, though at lower rates. Gallbladder-related events (including gallstones) appeared more often in the semaglutide group than placebo, which the NHS acknowledges as a known risk worth monitoring. Muscle loss is a separate concern that has attracted attention: rapid weight loss from any cause can reduce lean mass alongside fat, which is why prescribers and clinical guidance emphasise adequate protein intake and resistance exercise throughout treatment. The question of how to reduce side effect burden during treatment has practical answers, and dose titration is the main tool.

The side effects that require prompt medical attention

Some effects need more than watchful waiting. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as an uncommon but potentially serious risk with GLP-1 medicines including semaglutide. Severe, persistent stomach pain that radiates to the back, with or without vomiting, is the warning sign; it requires same-day medical attention, not a wait-and-see approach. Gallbladder symptoms (sharp upper-right abdominal pain, fever, jaundice) also warrant prompt assessment. Signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, rapid heartbeat) should prompt a 999 call. Dehydration from prolonged vomiting or diarrhoea can be more serious than it sounds, particularly if you have kidney disease; persistent symptoms that stop you keeping fluids down need clinical input. The NHS patient information page for semaglutide lists these warning signs in full, worth bookmarking, not just reading once. Anyone who suspects a side effect, expected or otherwise, can report it through the Yellow Card scheme; this data actively shapes MHRA monitoring decisions. Our prescribers discuss exactly these thresholds as part of the consultation at nume.

Where genuine uncertainty still sits

Honesty matters here. Semaglutide has a longer safety record in type 2 diabetes (through Ozempic and Rybelsus) than in weight management specifically, and that data is reassuring. But for weight-management doses of 2.4mg and above, most trials run to 68 or 72 weeks, and if you are weighing up whether Wegovy has long-term side effects worth factoring into your decision, it is worth understanding where the evidence base currently ends. Thyroid C-cell tumours appeared in rodent studies at high doses; this has not been observed in human trial populations to date, but it is why a personal or family history of medullary thyroid carcinoma remains a contraindication. The cardiovascular indication for semaglutide in eligible adults is supported by separate evidence, and the overall cardiovascular profile from the SELECT trial is positive, but that population overlaps with, rather than mirrors, the weight-management group. If you want the details of what evidence compares semaglutide directly with tirzepatide over time, our guide covering what the long-term side effects of Wegovy actually are covers that ground alongside the long-term semaglutide side-effect picture. A prescriber's job is to hold both the evidence and its limits in view, then apply them to your history. That is precisely what a clinical review at nume involves.